enviomycin
Small moleculeexperimental
Enviomycin is an antibiotic drug, isolated from Streptomyces griseoverticillatus var. tuberacticus. It is used in the treatment of tuberculosis. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Feb 18, 2015 (NCT02365623)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Elongation factor GINHIBITOR
Elongation factor G inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEnviomycin ↗
Also known as
- enviomicina
- enviomicina
- enviomycin
- enviomycin
- enviomycin
- enviomycin
- enviomycin
- enviomycin
- enviomycine
- enviomycine
- enviomycin sulfate
- enviomycinum
- enviomycinum
- tuberactinomycin n
- tuberactinomycin n
- tuberactinomycin n
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02354014 | Phase 2 | May 3, 2016 | Johnson and Johnson |
| NCT02365623 | Phase 2 | Feb 18, 2015 | Janssen Pharmaceutica NV, Johnson and Johnson |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Johnson and Johnson | For profit | 2 | 2 | 1 | 2015 |
| Janssen Pharmaceutica NV | For profit | 1 | 0 | 1 | 2015 |
2 organizations
Page 1 / 1